Evidence map›Paper›PMID 40779263›Full record

ArticleJAMA network open2025

Rural and Urban Differences in Prostate Cancer Recurrence.

Julia B Balmaceda, Aaron J Katz, Ying Cao, Katelyn Kane, Matthew W Chen, Deborah Usinger, Xinglei Shen

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia B BalmacedaDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City.
Aaron J KatzDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City.
Ying CaoDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City.
Katelyn KaneDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City.
Matthew W ChenDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City.
Deborah UsingerDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill.
Xinglei ShenDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Rural patients face unique barriers in obtaining high-quality cancer care. Research is lacking in determining whether these disparities translate to negative clinical outcomes. Objective: To determine if there are differences in the rate of biochemical recurrence in prostate cancer between rural and urban men. Design, Setting, and Participants: This cohort study used patient data that was abstracted from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, a population-based cohort that prospectively followed patients with newly diagnosed prostate cancer from the Rapid Case Ascertainment system of the North Carolina Central Cancer Registry from January 1, 2011, to June 30, 2013. Patients were identified who had received either surgery or radiation within 1 year of diagnosis. Data were analyzed from January 2011 to December 2022. Exposure: Patients were categorized as rural or urban using the Rural-Urban Continuum Code. Main Outcome and Measures: Recurrence was determined by prostate-specific antigen testing. Demographic differences between rural and urban patients were assessed using 2-sample independent t test and χ2 test. Prostate cancer recurrence was analyzed using Cox proportional hazard models. Results: A total of 778 patients were included with a median (IQR) follow-up of 4.6 (2.0 to 6.9) years and a mean (SD) age of 63 (7.4) years. Additionally, 213 were Black men (27.4%), 565 were White men (72.6%), 350 were Medicare insured (45.1%), 324 had an income ranging from $40 000 to $90 000 (43.1%), 370 were a National Comprehensive Cancer Network (NCCN) intermediate risk group (47.6%), 449 were treated with radical prostatectomy (57.7%), and 690 were in good to excellent health (88.7%) with 191 living in a rural setting (24.6%). On univariable analysis, rural residence (hazard ratio [HR], 2.19 [95% CI, 1.38 to 3.46]; P < .001), NCCN risk group (HR, 4.13 [95% CI, 2.25 to 7.57]; P < .001), and having had fewer than 12 biopsies (HR, 1.70 [95% CI, 1.08 to 2.67]; P = .02) were significantly associated with biochemical recurrence. On multivariable analysis adjusted for location of residence, marital status, overall health, number of cores biopsied, NCCN risk group, and treatment type, rural residence was significantly associated with recurrence (HR, 1.74 [95% CI, 1.07 to 2.82]; P = .03), while radiation therapy was inversely associated with recurrence (HR, 0.51 [95% CI, 0.31 to 0.85]; P = .01). Conclusions and Relevance: In this cohort study of patients with newly diagnosed prostate cancer, rural patients with prostate cancer had higher rates of biochemical recurrence. The etiology of this disparity is unclear but is likely multifactorial. Factors that may play a role include socioeconomic status, delay and disruptions in care, and access to multidisciplinary cancer care.

Indexed as

Neoplasm Recurrence, LocalProstatic NeoplasmsRural PopulationUrban PopulationAgedCohort StudiesHumansMaleMiddle AgedNorth CarolinaProspective StudiesProstate-Specific AntigenProstate-Specific Antigen

Identifiers

PMID40779263
PMCPMC12334958

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.